Pharmacy Interventions to Improve Chronic Disease Medication Refill

NCT00469365 | Completed Phase 3 DMC

• 1 other identifier: P01HS010871
• Study Type: interventional
• Target: 3,048
• Locations: 1 country
• Sites: 1

Brief Summary

Compare the effectiveness of 3 strategies by pharmacists to decrease the time to refill of prescriptions for common chronic diseases (diabetes, hypertension, hyperlipidemia, heart failure, depression, psychoses).

Conditions

Diabetes; Hypertension; Hyperlipidemia; Heart Diseases; Depression; Psychoses

Keywords

clinical trial, medication adherence, pharmacy intervention; Patients with specific chronic diseases

Outcome Measures

Primary Outcomes (1)

• The primary outcome was the number of days from the index date until the next date on which the patient filled a prescription for any qualified medication, or until the end of the study follow-up period.

Secondary Outcomes (1)

• Secondary outcomes included indicators for whether the patient filled any medication within 30 days for their chronic disease, and whether the patient filled any medication within 30 days.

Interventions

pharmacist contact with the patient via telephone BEHAVIORAL

Pharmacist contact with the patient's physician via fax BEHAVIORAL

Usual care BEHAVIORAL

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients who were at least 7 days overdue for a qualified prescription were identified on a weekly basis (i.e. every Monday morning) using the centralized computer database. A qualified prescription was defined as having at least 2 refills remaining, a duration of at least a 30 days' supply, and having been written for any one of a number of chronic disease medications identified by a clinical pharmacist (A.M.W.). The medications of interest were those indicated for chronic treatment of diabetes mellitus, hypertension, hyperlipidemia, heart failure, depression, and psychoses. Medications that treat any combination of the specified diseases were allowed.

Sponsors & Collaborators

• Medical University of South Carolina: lead
• Agency for Healthcare Research and Quality (AHRQ): collaborator

Study Sites (1)

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus; Hypertension; Hyperlipidemias; Heart Diseases; Depression; Psychotic Disorders; Medication Adherence

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Vascular Diseases; Cardiovascular Diseases; Dyslipidemias; Lipid Metabolism Disorders; Behavioral Symptoms; Behavior; Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Patient Compliance; Patient Acceptance of Health Care; Treatment Adherence and Compliance; Health Behavior

Study Officials

• Paul J Nietert, PhD

  Medical University of South Carolina

  PRINCIPAL INVESTIGATOR

• Barbara C Tilley, PhD

  Medical University of South Carolina

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: May 3, 2007
• First Posted: May 4, 2007
• Study Start: January 1, 2006
• Study Completion: August 1, 2006
• Last Updated: November 26, 2008

Record last verified: 2007-05

Locations

US (1)